Cancer Supportive Care Drugs Market Size, Share, Growth Analysis Report 2032

Cancer Supportive Care Drugs Market Insights

The global Cancer Supportive Care Drugs Market size was valued at USD 21.00 Billion in 2023 and is predicted to reach USD 25.31 Billion by the end of 2032. The market is expected to grow with a CAGR of 2.1% during the forecast period. The report analyzes the global Cancer Supportive Care Drugs Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Cancer Supportive Care Drugs industry.

Request Free Sample

Cancer Supportive Care Drugs Market: Industry Perspective

Cancer treatment causes many side effects. Some of the side effects include pain, fatigue, loss of confidence and self-esteem, changes in sexuality, menopausal symptoms for women, fertility problems, lymphoedema, cognitive changes, depression, and other side effects. Some of these side effects are very serious medical conditions that need to be treated and others are inconvenient or upsetting but are not harmful to health. The rise in such types of incidences of the disease and the growing need to manage these effectively has led to the growth in the market for cancer supportive care drugs.

The report covers forecasts and analysis for the global cancer supportive care drugs market. The study provides historic data from 2018 to 2022 along with forecasts from 2024 to 2032 based on revenue (USD Million). In-depth secondary research is used to ascertain overall market size, top industry players, top treatments, industry associations, etc. Macro-economic indicators such as healthcare industry outlook, healthcare spending, research funding, GDP along with company websites, company annual reports, white papers, financial reports, and other sources have also been considered to arrive at the indicated market numbers.

Request Free Sample

Cancer Supportive Care Drugs Market Growth Dynamics

The study also includes drivers and restraints for cancer supportive care drugs along with the impact they have on the demand over the forecast period. Besides, the report includes the study of opportunities and trends available in the cancer supportive care drugs market on a global level. The market for cancer supportive drugs has a huge demand and is likely to grow in the coming future. As per the stats provided by GLOBOCAN, 14.5 million new cancer cases were diagnosed worldwide in the year 2013. As per WHO, the growth in cancer cases is likely to raise by 75% in the next decade with more than 20 million new cancer cases. Cancer is highly dominant in middle and lower income countries due to a lack of apt healthcare infrastructure to effectively combat this condition. Similarly, 65% of the total worldwide death related to cancer was reported from less developed regions.

Cancer Supportive Care Drugs Market Segmentation Analysis

The study provides a decisive view of the cancer supportive care drugs market by segmenting the market based on product, cancer type, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2024 to 2032. Based on cancer type the market is segmented into granulocyte-colony stimulating factors (G-CSF), erythropoietin-stimulating agents (ESA), antiemetics, bisphosphonates, opioids, non-steroidal anti-inflammatory drugs (NSAID), and others. Granulocyte-colony stimulating factors and erythropoietin-stimulating agents are likely to grow at high CARG owing to the shift from biologics to biosimilars. The shift is backed by high mortality, patent loss, major safety issues associated with narcotic agents, and addiction.

Based on cancer type the market is segmented into breast cancer, lung cancer, melanoma, prostate cancer, and other cancers. The breast cancer segment is expected to grow at the fastest rate in the global market over the forecast period. Regional segmentation includes the current and forecast demand for the Asia Pacific, North America, Latin America, Europe, and Middle East & Africa with its further bifurcation into major countries.

The report also provides company market share analysis in order to give a broader view of the key players in the market. Industry insights and information is delivered in the required format. ZMR develops a list of industry players (manufacturers), distributors, retailers and industry experts. Some of the players included in the cancer supportive care drugs market are Johnson & Johnson, Amgen, Merck, Heron Pharma, Roche, Helsinn Healthcare, and Tesaro.

Cancer Supportive Care Drugs Market: Report Scope

The report segments the cancer supportive care drugs market as follows:

Global Cancer Supportive Care Drugs Market: Drug Class Segment Analysis

• Granulocyte-Colony Stimulating Factors (G-CSF)
• Erythropoietin-Stimulating Agents (ESA)
• Antiemetic’s
• Bisphosphonates
• Opioids
• Non-Steroidal Anti-Inflammatory Drugs (NSAID)
• Others

Global Cancer Supportive Care Drugs Market: Cancer Type Segment Analysis

• Breast Cancer
• Lung Cancer
• Melanoma
• Prostate Cancer
• Other Cancers

Global Cancer Supportive Care Drugs Market: Regional Segment Analysis

• North America
  • U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa